Drugs / Changkang granules
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06753890 | Dec 2024 → Nov 2026 expected | irritable bowel syndrome | Tasly Pharmaceutical Group Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Changkang granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06753890 ↗ |
| Route | Oral | “oral” NCT06753890 ↗ |